4 Amendments of Silvia SARDONE related to 2019/2816(RSP)
Amendment 157 #
Paragraph 16
Amendment 161 #
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicine by drawing up multiple comparative environmental risk assessment tables without compromising access to safe and effective pharmacological treatments;
Amendment 166 #
Paragraph 16
16. Considers thatit inappropriate to include the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines; when it comes to ensuring that patients have access to safe and effective pharmaceutical treatments;
Amendment 231 #
Paragraph 32
32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms into comprehensive monitoring, also with regard to environmental effects, as the current surveillance system (pharmacovigilance) is notand environmental monitoring, in order to ensure adequately and systematically covering scrutiny of the environmental data deficit;